Ignite Creation Date:
2024-10-25 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06553209
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-11
Brief Title:
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Double-blind SingleMultiple Dose Escalation Placebo-controlled Phase I Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Immunogenicity of CM512 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind singlemultiple dose escalation placebo-controlled phase I study evaluating the safety tolerability pharmacokinetics pharmacodynamics and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None